{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:45:53Z","timestamp":1787946353394,"version":"build-2784847793"},"reference-count":167,"publisher":"The Royal Society","issue":"1957","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\u2013National Institutes of Cancer","award":["R00CA248836"],"award-info":[{"award-number":["R00CA248836"]}]},{"DOI":"10.13039\/100007038","name":"Lung Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007038","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Margaret E. Early Biomedical Research Trust (T.K.H.) and V-Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The epidermal growth factor receptor, or EGFR, is one of the most frequently altered oncogenes in human cancer and is a critical therapeutic target. EGFR alterations span a broad spectrum, including gene amplification, point mutations, truncations, in-frame insertions or deletions, and fusions, yet their mutational distribution is cancer type-specific. This distribution impacts the effectiveness of EGFR-targeted therapies across EGFR-mutant cancers. This review will cover what is currently known about the EGFR-driven cancer landscape in the following cell lineages: lung, brain, colon, breast and bladder.<\/jats:p>\n                  <jats:p>This article is part of the discussion meeting issue \u2018Epidermal growth factor receptor after 40 years\u2019.<\/jats:p>","DOI":"10.1098\/rstb.2024.0501","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:15Z","timestamp":1787814555000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of lineage-specific epidermal growth factor receptor mutations in cancer"],"prefix":"10.1098","volume":"381","author":[{"given":"Amy","family":"Rios","sequence":"first","affiliation":[{"name":"Molecular Biology Interdepartmental Doctoral Program, University of California 1 , Los Angeles, CA, 90095, USA"},{"name":"Department of Molecular and Medical Pharmacology, University of California 2 , Los Angeles, CA, 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California 3 , Los Angeles, CA, 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"Jorge","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, University of California 2 , Los Angeles, CA, 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California 3 , Los Angeles, CA, 90095, USA"},{"name":"Undergraduate Research Center, University of California 4 , Los Angeles, CA, 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizelle G.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, University of California 2 , Los Angeles, CA, 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California 3 , Los Angeles, CA, 90095, USA"},{"name":"Undergraduate Research Center, University of California 4 , Los Angeles, CA, 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, University of California 2 , Los Angeles, CA, 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California 3 , Los Angeles, CA, 90095, USA"},{"name":"Undergraduate Research Center, University of California 4 , Los Angeles, CA, 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0008-5246","authenticated-orcid":false,"given":"Tikvah K.","family":"Hayes","sequence":"additional","affiliation":[{"name":"Department of Molecular and Medical Pharmacology, University of California 2 , Los Angeles, CA, 90095, USA"},{"name":"Jonsson Comprehensive Cancer Center, University of California 3 , Los Angeles, CA, 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"2026082703091056200_RSTB20240501C1","doi-asserted-by":"crossref","first-page":"33793","DOI":"10.1074\/jbc.X800008200","article-title":"Origins of growth factors: NGF and EGF","volume":"283","author":"Cohen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2026082703091056200_RSTB20240501C2","first-page":"6192187","article-title":"Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation","volume":"2018","author":"Juri\u0161i\u0107","year":"2018","journal-title":"Anal. Cell. Pathol. (Amst.)"},{"key":"2026082703091056200_RSTB20240501C3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/307521a0","article-title":"Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences","volume":"307","author":"Downward","year":"1984","journal-title":"Nature"},{"key":"2026082703091056200_RSTB20240501C4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.21037\/tlcr-19-359","article-title":"The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer","volume":"9","author":"Zhao","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"2026082703091056200_RSTB20240501C5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"2026082703091056200_RSTB20240501C6","first-page":"3093","article-title":"Endocytosis and intracellular trafficking of ErbBs","volume":"314","author":"Sorkin","year":"2008","journal-title":"Exp. Cell Res."},{"key":"2026082703091056200_RSTB20240501C7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/jcb.20876","article-title":"Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin \u03b21 and CRM1","volume":"98","author":"Lo","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"2026082703091056200_RSTB20240501C8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev.biophys.37.032807.125829","article-title":"Structure-based view of epidermal growth factor receptor regulation","volume":"37","author":"Ferguson","year":"2008","journal-title":"Annu. Rev. Biophys."},{"key":"2026082703091056200_RSTB20240501C9","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.12688\/f1000research.9025.1","article-title":"EGF receptor ligands: recent advances","volume":"5","author":"Singh","year":"2016","journal-title":"F1000Res"},{"key":"2026082703091056200_RSTB20240501C10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/ijmm.2017.3036","article-title":"The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)","volume":"40","author":"Ardito","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"2026082703091056200_RSTB20240501C11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2026082703091056200_RSTB20240501C12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0092-8674(92)90167-B","article-title":"The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to RAS signaling","volume":"70","author":"Lowenstein","year":"1992","journal-title":"Cell"},{"key":"2026082703091056200_RSTB20240501C13","first-page":"5192","article-title":"Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor","volume":"14","author":"Batzer","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"2026082703091056200_RSTB20240501C14","doi-asserted-by":"crossref","first-page":"30199","DOI":"10.1074\/jbc.273.46.30199","article-title":"Regulation of the p85\/p110\u0251 phosphatidylinositol 3'-kinase. Distinct roles for the N-terminal and C-terminal SH2 domains","volume":"273","author":"Yu","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2026082703091056200_RSTB20240501C15","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1016\/S0021-9258(18)98375-4","article-title":"Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit","volume":"268","author":"Carpenter","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2026082703091056200_RSTB20240501C16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703091056200_RSTB20240501C17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(03)00013-9","article-title":"Requirement of autophosphorylated tyrosine 992 of EGF receptor and its docking protein phospholipase C\u03b31 for membrane ruffle formation","volume":"536","author":"Nogami","year":"2003","journal-title":"FEBS Lett."},{"key":"2026082703091056200_RSTB20240501C18","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.1411571","article-title":"Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C","volume":"258","author":"Nishizuka","year":"1992","journal-title":"Science"},{"key":"2026082703091056200_RSTB20240501C19","doi-asserted-by":"crossref","first-page":"G1227","DOI":"10.1152\/ajpgi.00253.2004","article-title":"EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes","volume":"287","author":"Andl","year":"2004","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"2026082703091056200_RSTB20240501C20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1074\/jbc.M207289200","article-title":"STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor","volume":"278","author":"Kloth","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2026082703091056200_RSTB20240501C21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"key":"2026082703091056200_RSTB20240501C22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer\u2014new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703091056200_RSTB20240501C23","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1172\/JCI31871","article-title":"Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas","volume":"117","author":"Gao","year":"2007","journal-title":"J. Clin. Invest."},{"key":"2026082703091056200_RSTB20240501C24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/1566524023362456","article-title":"The role of STATs in apoptosis","volume":"2","author":"Battle","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"2026082703091056200_RSTB20240501C25","first-page":"831","article-title":"Autocrine interaction between TGF \u0251 and the EGF-receptor: quantitative requirements for induction of the malignant phenotype","volume":"4","author":"Di Marco","year":"1989","journal-title":"Oncogene"},{"key":"2026082703091056200_RSTB20240501C26","first-page":"407","article-title":"Transforming growth factor-\u0251 expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-RAS protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-\u0251 complementary DNA leads to transformation","volume":"1","author":"Ciardiello","year":"1990","journal-title":"Cell Growth Differ."},{"key":"2026082703091056200_RSTB20240501C27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mc.2940020102","article-title":"Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor \u0251 cDNA","volume":"2","author":"Shankar","year":"1989","journal-title":"Mol. Carcinog."},{"key":"2026082703091056200_RSTB20240501C28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","article-title":"Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody","volume":"80","author":"Kawamoto","year":"1983","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703091056200_RSTB20240501C29","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026082703091056200_RSTB20240501C30","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"2026082703091056200_RSTB20240501C31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cac2.12005","article-title":"Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun. (Lond)."},{"key":"2026082703091056200_RSTB20240501C32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703091056200_RSTB20240501C33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.3494307","article-title":"A chimeric, ligand-binding v-erbB\/EGF receptor retains transforming potential","volume":"236","author":"Riedel","year":"1987","journal-title":"Science"},{"key":"2026082703091056200_RSTB20240501C34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026082703091056200_RSTB20240501C35","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res."},{"key":"2026082703091056200_RSTB20240501C36","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"2026082703091056200_RSTB20240501C37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-20-1165","article-title":"Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations","volume":"11","author":"Carrot-Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2018.08.019","article-title":"Integrated analysis of genetic ancestry and genomic alterations across cancers","volume":"34","author":"Yuan","year":"2018","journal-title":"Cancer Cell"},{"key":"2026082703091056200_RSTB20240501C40","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/bjc.2013.511","article-title":"EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice","volume":"109","author":"Gahr","year":"2013","journal-title":"Br. J. Cancer"},{"key":"2026082703091056200_RSTB20240501C41","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"2026082703091056200_RSTB20240501C42","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"2026082703091056200_RSTB20240501C43","volume-title":"PDQ cancer information summaries","author":"PDQ Adult Treatment Editorial Board","year":"2002"},{"key":"2026082703091056200_RSTB20240501C44","first-page":"100237","article-title":"Efficacy of targeted inhibitors in metastatic lung squamous cell carcinoma with EGFR or ALK alterations","volume":"2","author":"Lewis","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"2026082703091056200_RSTB20240501C45","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (MutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann. Oncol."},{"key":"2026082703091056200_RSTB20240501C46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"2026082703091056200_RSTB20240501C47","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2026082703091056200_RSTB20240501C48","doi-asserted-by":"crossref","first-page":"e107161","DOI":"10.1371\/journal.pone.0107161","article-title":"Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"2026082703091056200_RSTB20240501C49","doi-asserted-by":"crossref","first-page":"111246","DOI":"10.18632\/oncotarget.22768","article-title":"Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients","volume":"8","author":"Su","year":"2017","journal-title":"Oncotarget"},{"key":"2026082703091056200_RSTB20240501C50","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41467-022-34398-z","article-title":"Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations","volume":"13","author":"van Alderwerelt van Rosenburgh","year":"2022","journal-title":"Nat. Commun."},{"key":"2026082703091056200_RSTB20240501C51","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-19-0780","article-title":"The EGFR exon 19 mutant L747-A750&gt;P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma","volume":"25","author":"Truini","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.lungcan.2014.09.014","article-title":"Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer","volume":"86","author":"Kaneda","year":"2014","journal-title":"Lung Cancer"},{"key":"2026082703091056200_RSTB20240501C53","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/JTO.0b013e31818071f3","article-title":"Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database","volume":"3","author":"Murray","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C54","doi-asserted-by":"crossref","first-page":"102080","DOI":"10.1016\/j.canep.2021.102080","article-title":"Uncommon EGFR mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes","volume":"76","author":"John","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"2026082703091056200_RSTB20240501C55","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"2026082703091056200_RSTB20240501C56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026082703091056200_RSTB20240501C57","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2026082703091056200_RSTB20240501C58","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtho.2023.01.086","article-title":"Distribution and detectability of EGFRexon 20 insertion variants in NSCLC","volume":"18","author":"Ou","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C59","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"2026082703091056200_RSTB20240501C60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026082703091056200_RSTB20240501C61","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1200\/JCO-25-00763","article-title":"Zipalertinib in patients with epidermal growth factor receptor exon 20 insertion-positive non-small cell lung cancer previously treated with platinum-based chemotherapy with or without amivantamab","volume":"43","author":"Piotrowska","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026082703091056200_RSTB20240501C62","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C63","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1016\/j.cllc.2025.06.005","article-title":"Clinical outcomes of compound EGFR mutations in non-small cell lung cancer: a national, retrospective, multicenter study","volume":"26","author":"Atlagh","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"2026082703091056200_RSTB20240501C64","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/JTO.0000000000000130","article-title":"Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations","volume":"9","author":"Gazdar","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C65","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited lung cancer syndromes targeting never smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"2026082703091056200_RSTB20240501C66","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/s43018-024-00840-y","article-title":"Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors","volume":"5","author":"Burr","year":"2024","journal-title":"Nat. Cancer"},{"key":"2026082703091056200_RSTB20240501C67","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.jtho.2022.07.1080","article-title":"EP16.03-019 landscape of EGFR extracellular domain mutations in advanced non small cell lung carcinoma","volume":"17","author":"Solomon","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C68","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/s41467-024-45594-4","article-title":"Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","volume":"15","author":"Hayes","year":"2024","journal-title":"Nat. Commun."},{"key":"2026082703091056200_RSTB20240501C69","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.1073\/pnas.0510284103","article-title":"Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors","volume":"103","author":"Ji","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703091056200_RSTB20240501C70","first-page":"319","article-title":"EGFRvIII mutation in lung cancer correlates with increased EGFR copy number","volume":"17","author":"Sasaki","year":"2007","journal-title":"Oncol. Rep."},{"key":"2026082703091056200_RSTB20240501C71","first-page":"1251","article-title":"Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene","volume":"6","author":"Batra","year":"1995","journal-title":"Cell Growth Differ."},{"key":"2026082703091056200_RSTB20240501C72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1556-0864(15)30407-X","article-title":"Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma","volume":"1","author":"Ohtsuka","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C73","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00432-015-1989-z","article-title":"Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma","volume":"141","author":"Matsumura","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2026082703091056200_RSTB20240501C74","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1038\/onc.2009.199","article-title":"Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer","volume":"28","author":"Hirsch","year":"2009","journal-title":"Oncogene"},{"key":"2026082703091056200_RSTB20240501C75","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C76","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/s41467-021-21613-6","article-title":"Structure\u2013function analysis of oncogenic EGFR kinase domain duplication reveals insights into activation and a potential approach for therapeutic targeting","volume":"12","author":"Du","year":"2021","journal-title":"Nat. Commun."},{"key":"2026082703091056200_RSTB20240501C77","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/ijc.31895","article-title":"Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC","volume":"144","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"key":"2026082703091056200_RSTB20240501C78","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/JTO.0000000000000586","article-title":"Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication","volume":"10","author":"Baik","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/2159-8290.CD-15-0654","article-title":"EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib","volume":"5","author":"Gallant","year":"2015","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C80","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1158\/0008-5472.CAN-04-3388","article-title":"Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer","volume":"65","author":"Muller-Tidow","year":"2005","journal-title":"Cancer Res."},{"key":"2026082703091056200_RSTB20240501C81","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703091056200_RSTB20240501C82","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C83","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"2026082703091056200_RSTB20240501C84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026082703091056200_RSTB20240501C85","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"2026082703091056200_RSTB20240501C86","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s00432-020-03239-1","article-title":"Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes","volume":"146","author":"Mu","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2026082703091056200_RSTB20240501C87","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.21037\/tcr-24-406","article-title":"Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges","volume":"13","author":"Su","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C88","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2017.04.003","article-title":"Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S\/R) together with C797S\/R and L792F\/H mutations in one EGFR (L858R\/T790M) NSCLC patient who progressed on osimertinib","volume":"108","author":"Ou","year":"2017","journal-title":"Lung Cancer"},{"key":"2026082703091056200_RSTB20240501C89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"2026082703091056200_RSTB20240501C90","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/ijms25020705","article-title":"Preclinical anticipation of on- and off-target resistance mechanisms to anti-cancer drugs: a systematic review","volume":"25","author":"Dziubanska-Kusibab","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C91","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"2026082703091056200_RSTB20240501C92","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C93","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-18-3829","article-title":"On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation","volume":"25","author":"Brown","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C94","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1038\/s41598-024-53006-2","article-title":"Survival prediction of glioblastoma patients using modern deep learning and machine learning techniques","volume":"14","author":"Babaei Rikan","year":"2024","journal-title":"Scient. Rep."},{"key":"2026082703091056200_RSTB20240501C95","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2015.09.002","article-title":"EGFR mutation promotes glioblastoma through epigenome and transcription factor network remodeling","volume":"60","author":"Liu","year":"2015","journal-title":"Mol. Cell."},{"key":"2026082703091056200_RSTB20240501C96","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"Furnari","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703091056200_RSTB20240501C97","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev."},{"key":"2026082703091056200_RSTB20240501C98","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"2026082703091056200_RSTB20240501C99","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/PO.19.00295","article-title":"Exploring predictors of response to dacomitinib in EGFR-amplified recurrent glioblastoma","volume":"4","author":"Chi","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"2026082703091056200_RSTB20240501C100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1750-3639.2009.00318.x","article-title":"EGFRvIII-targeted vaccination therapy of malignant glioma","volume":"19","author":"Choi","year":"2009","journal-title":"Brain Pathol."},{"key":"2026082703091056200_RSTB20240501C101","doi-asserted-by":"crossref","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2026082703091056200_RSTB20240501C102","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.1219817110","article-title":"Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma","volume":"110","author":"Choi","year":"2013","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703091056200_RSTB20240501C103","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1371\/journal.pmed.0030485","article-title":"Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain","volume":"3","author":"Lee","year":"2006","journal-title":"PLoS Med."},{"key":"2026082703091056200_RSTB20240501C104","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/cancers10120489","article-title":"Finding the right way to target EGFR in glioblastomas; lessons from lung adenocarcinomas","volume":"10","author":"Gao","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026082703091056200_RSTB20240501C105","first-page":"vdz051","article-title":"EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand","volume":"2","author":"Hoogstrate","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"2026082703091056200_RSTB20240501C106","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1038\/s41598-022-18348-9","article-title":"Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment: integrated computational analysis and in vitro study","volume":"12","author":"Hermawan","year":"2022","journal-title":"Scient. Rep."},{"key":"2026082703091056200_RSTB20240501C107","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/1078-0432.CCR-15-1046","article-title":"EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs","volume":"21","author":"Kobayashi","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2018.04.006","article-title":"Case report: osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L\/V774M mutation complex","volume":"121","author":"Yang","year":"2018","journal-title":"Lung Cancer"},{"key":"2026082703091056200_RSTB20240501C109","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1073\/pnas.84.19.6899","article-title":"Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification","volume":"84","author":"Wong","year":"1987","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026082703091056200_RSTB20240501C110","doi-asserted-by":"crossref","first-page":"e2434","DOI":"10.1038\/cddis.2016.318","article-title":"Glioblastoma, hypoxia and autophagy: a survival-prone \u2018m\u00e9nage-\u00e0-trois\u2019","volume":"7","author":"Jawhari","year":"2016","journal-title":"Cell Death Dis."},{"key":"2026082703091056200_RSTB20240501C111","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1128\/MCB.16.11.6009","article-title":"Transcriptional activation of the human epidermal growth factor receptor promoter by human p53","volume":"16","author":"Ludes-Meyers","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"2026082703091056200_RSTB20240501C112","doi-asserted-by":"crossref","first-page":"11110","DOI":"10.3390\/ijms241311110","article-title":"An overview of EGFR mechanisms and their implications in targeted therapies for glioblastoma","volume":"24","author":"Rodriguez","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C113","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/2159-8290.CD-13-0879","article-title":"EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing","volume":"4","author":"Francis","year":"2014","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C114","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/ijms19010229","article-title":"The influence of EGFR inactivation on the radiation response in high grade glioma","volume":"19","author":"Alexandru","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C115","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2990.2008.00977.x","article-title":"Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma","volume":"35","author":"Idbaih","year":"2009","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2026082703091056200_RSTB20240501C116","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell."},{"key":"2026082703091056200_RSTB20240501C117","first-page":"vdab133","article-title":"Receptor tyrosine kinases as druggable targets in glioblastoma: do signaling pathways matter?","volume":"3","author":"Qin","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"2026082703091056200_RSTB20240501C118","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms22041831","article-title":"Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme","volume":"22","author":"Tilak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C119","first-page":"vdae229","article-title":"Transcriptomic analysis of EGFR co-expression and activation in glioblastoma reveals associations with its ligands","volume":"7","author":"Ghisai","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"2026082703091056200_RSTB20240501C120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/2159-8290.CD-11-0287","article-title":"Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers","volume":"2","author":"Barkovich","year":"2012","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathol-011110-130324","article-title":"Glioblastoma: from molecular pathology to targeted treatment","volume":"9","author":"Cloughesy","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"2026082703091056200_RSTB20240501C122","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/2159-8290.CD-12-0502","article-title":"De-repression of PDGFR\u03b2 transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients","volume":"3","author":"Akhavan","year":"2013","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C123","first-page":"vdaa020","article-title":"EGFR blockade in GBM brain tumor stem cells synergizes with JAK2\/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo","volume":"2","author":"Jensen","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"2026082703091056200_RSTB20240501C124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"2026082703091056200_RSTB20240501C125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/jpm11040258","article-title":"Diagnosis and management of glioblastoma: a comprehensive perspective","volume":"11","author":"Gilard","year":"2021","journal-title":"J. Pers. Med."},{"key":"2026082703091056200_RSTB20240501C126","doi-asserted-by":"crossref","first-page":"8835","DOI":"10.3390\/ijms23168835","article-title":"Molecular biomarkers in glioblastoma: a systematic review and meta-analysis","volume":"23","author":"Sareen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the cancer dependency map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"2026082703091056200_RSTB20240501C128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026082703091056200_RSTB20240501C129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4251\/wjgo.v5.i5.97","article-title":"RAS signaling pathways, mutations and their role in colorectal cancer","volume":"5","author":"Zenonos","year":"2013","journal-title":"World J. Gastrointest. Oncol."},{"key":"2026082703091056200_RSTB20240501C130","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2026082703091056200_RSTB20240501C131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/vaccines10040499","article-title":"EGFR-based targeted therapy for colorectal cancer\u2013promises and challenges","volume":"10","author":"Janani","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026082703091056200_RSTB20240501C132","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr. Oncol."},{"key":"2026082703091056200_RSTB20240501C133","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","article-title":"The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer","volume":"71","author":"Mayer","year":"1993","journal-title":"Cancer"},{"key":"2026082703091056200_RSTB20240501C134","doi-asserted-by":"crossref","first-page":"12828","DOI":"10.3390\/ijms222312828","article-title":"The role of EREG\/EGFR pathway in tumor progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"2026082703091056200_RSTB20240501C135","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/ijc.32499","article-title":"Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab","volume":"146","author":"Kim","year":"2020","journal-title":"Int. J. Cancer"},{"key":"2026082703091056200_RSTB20240501C136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12920-022-01294-w","article-title":"Somatic targeted mutation profiling of colorectal cancer precursor lesions","volume":"15","author":"dos Santos","year":"2022","journal-title":"BMC Med. Genomics"},{"key":"2026082703091056200_RSTB20240501C137","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026082703091056200_RSTB20240501C138","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol."},{"key":"2026082703091056200_RSTB20240501C139","doi-asserted-by":"crossref","first-page":"625","DOI":"10.5858\/arpa.2016-0554-CP","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology","volume":"141","author":"Sepulveda","year":"2017","journal-title":"Arch Pathol. Lab. Med."},{"key":"2026082703091056200_RSTB20240501C140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.21037\/jgo-24-458","article-title":"Response to anti-EGFR therapy in chemo-refractory right-sided RAS wild-type metastatic colorectal cancer: a case report and literature review","volume":"16","author":"Xiao","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"2026082703091056200_RSTB20240501C141","doi-asserted-by":"crossref","first-page":"e1004271","DOI":"10.1371\/journal.pgen.1004271","article-title":"Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing","volume":"10","author":"Mohan","year":"2014","journal-title":"PLoS Genet."},{"key":"2026082703091056200_RSTB20240501C142","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat. Med."},{"key":"2026082703091056200_RSTB20240501C143","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","article-title":"Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution","volume":"4","author":"Misale","year":"2014","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C144","first-page":"4673","article-title":"RAS mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma","volume":"30","author":"Dempke","year":"2010","journal-title":"Anticancer Res."},{"key":"2026082703091056200_RSTB20240501C145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026082703091056200_RSTB20240501C146","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"2026082703091056200_RSTB20240501C147","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10549-012-2289-9","article-title":"Role of epidermal growth factor receptor in breast cancer","volume":"136","author":"Masuda","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"2026082703091056200_RSTB20240501C148","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2026082703091056200_RSTB20240501C149","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10549-017-4216-6","article-title":"\u0394Np63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells","volume":"163","author":"Holcakova","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"2026082703091056200_RSTB20240501C150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"2026082703091056200_RSTB20240501C151","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":"EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Bhargava","year":"2005","journal-title":"Mod. Pathol."},{"key":"2026082703091056200_RSTB20240501C152","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr2850","article-title":"Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice","volume":"13","author":"Burga","year":"2011","journal-title":"Breast Cancer Res."},{"key":"2026082703091056200_RSTB20240501C153","doi-asserted-by":"crossref","first-page":"e0134398","DOI":"10.1371\/journal.pone.0134398","article-title":"The epidermal growth factor receptor (EGFR \/HER-1) gatekeeper mutation T790M is present in European patients with early breast cancer","volume":"10","author":"Bemanian","year":"2015","journal-title":"PLoS One"},{"key":"2026082703091056200_RSTB20240501C154","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2857","article-title":"Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy","volume":"13","author":"Teng","year":"2011","journal-title":"Breast Cancer Res."},{"key":"2026082703091056200_RSTB20240501C155","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/sj.bjc.6602557","article-title":"Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors","volume":"92","author":"Weber","year":"2005","journal-title":"Br. J. Cancer"},{"key":"2026082703091056200_RSTB20240501C156","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4161\/cbt.7.11.6847","article-title":"Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways","volume":"7","author":"Yu","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"2026082703091056200_RSTB20240501C157","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"key":"2026082703091056200_RSTB20240501C158","first-page":"3081","article-title":"Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer","volume":"60","author":"Tang","year":"2000","journal-title":"Cancer Res."},{"key":"2026082703091056200_RSTB20240501C159","doi-asserted-by":"crossref","first-page":"108037","DOI":"10.1016\/j.bioorg.2024.108037","article-title":"Epidermal growth factor receptor mutations in breast cancer: therapeutic challenges and way forward","volume":"154","author":"Shetty","year":"2025","journal-title":"Bioorg. Chem."},{"key":"2026082703091056200_RSTB20240501C160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-2187-5-8","article-title":"EGFR\/Met association regulates EGFR TKI resistance in breast cancer","volume":"5","author":"Mueller","year":"2010","journal-title":"J. Mol. Signal."},{"key":"2026082703091056200_RSTB20240501C161","doi-asserted-by":"crossref","first-page":"508","DOI":"10.18632\/oncotarget.28747","article-title":"Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: insights into RTK dependent and independent mechanisms","volume":"16","author":"Shyamsunder","year":"2025","journal-title":"Oncotarget"},{"key":"2026082703091056200_RSTB20240501C162","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.humpath.2011.11.016","article-title":"High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues","volume":"43","author":"Chaux","year":"2012","journal-title":"Hum. Pathol."},{"key":"2026082703091056200_RSTB20240501C163","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1038\/s41388-020-01465-y","article-title":"EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer","volume":"39","author":"Rose","year":"2020","journal-title":"Oncogene"},{"key":"2026082703091056200_RSTB20240501C164","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bju.15006","article-title":"Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions","volume":"125","author":"Madison","year":"2020","journal-title":"BJU Int."},{"key":"2026082703091056200_RSTB20240501C165","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41591-018-0007-9","article-title":"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer","volume":"24","author":"Robichaux","year":"2018","journal-title":"Nat. Med."},{"key":"2026082703091056200_RSTB20240501C166","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/2159-8290.CD-20-1598","article-title":"Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I\/II trial","volume":"11","author":"Riely","year":"2021","journal-title":"Cancer Discov."},{"key":"2026082703091056200_RSTB20240501C167","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0501\/6162290\/rstb.2024.0501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2024.0501\/6162290\/rstb.2024.0501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:09:39Z","timestamp":1787814579000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/381\/1957\/20240501\/483096\/Impact-of-lineage-specific-epidermal-growth-factor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":167,"journal-issue":{"issue":"1957","published-online":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2024.0501","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"20240501"}}